Lorazin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorazin

Quick Facts

Property Description
Active ingredient Lorazepam
Pharmacological class Benzodiazepine / Central Nervous System (CNS) Depressant
Dosage Forms Tablet, Oral Solution, Injectable Solution, Capsule
Origin Synthetic (Chemically Synthesized)

What Type of Medicine is Lorazin and Its Pharmacological Class?

Lorazin is a commercial name for the active substance lorazepam, which belongs to the benzodiazepine pharmacological class, an established category of psychoactive drugs. This medicine is a synthetic compound that is categorized broadly as a Central Nervous System (CNS) Depressant due to its action of slowing down specific functions within the brain and spinal cord. This classification confirms that the medicine works centrally to reduce neural activity, a property that is clinically recognized across numerous pharmacological studies. As a potent compound, Lorazin is strictly a prescription-only medicine, characterized as a single active ingredient product (monotherapy) focused entirely on the effects of lorazepam.

The core identity of lorazepam places it among the intermediate-acting CNS depressants, possessing an elimination half-life typically ranging from 10 to 20 hours. This property ensures that the effects are predictable, lasting a moderate duration that avoids the very long persistence associated with some other depressants. The classification as a benzodiazepine immediately defines its fundamental action as modulating the brain's inhibitory systems.


The Active Ingredient Lorazepam and Available Forms

The active ingredient in Lorazin is lorazepam, a small molecule chemical entity. To meet different patient needs, Lorazin is manufactured in several versatile dosage forms, which include standard oral tablets, a concentrated oral solution, specialized extended-release capsules, and an injectable solution for use in acute clinical situations. The availability of the oral solution concentrate is a distinguishing feature, offering precise dosing flexibility that is beneficial for patients requiring fine dose adjustments.

These diverse preparations dictate the various routes of administration the medicine can utilize, which include oral ingestion, sublingual absorption, and both intravenous (IV) injection and intramuscular (IM) injection. The injectable form utilizes an aqueous solution base with specific co-solvents to ensure stable and effective delivery in non-oral routes.


What is the General Therapeutic Purpose of Lorazin?

The general therapeutic purpose of Lorazin is to relieve conditions characterized by states of excessive nervous excitement and tension by acting as an effective quietening agent. This relief is achieved because lorazepam fundamentally functions as a GABAergic agent, which means it enhances the effect of GABA (gamma-aminobutyric acid), the primary natural quieting messenger in the brain.

By amplifying this natural inhibitory signal, Lorazin achieves widespread neuronal hyperpolarization, resulting in powerful sedative, anxiolytic (anxiety-reducing), and muscle relaxant effects. These core physiological actions allow the medicine to stabilize overstimulated neural states, thereby facilitating both mental and physical relaxation. Its general therapeutic utility is often observed in managing acute, time-sensitive states of agitation where prompt and reliable central quieting is essential.

Regulatory References

  1. Lorazepam (Ativan) Official Label
  2. Lorazepam Pharmacokinetics (NCBI)

What side effects are possible with Lorazin?

Official Safety Profile and Adverse Reactions

The safety profile of Lorazepam (Lorazin) is formally organized by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. These classifications define the officially recognized risks associated with the medicine.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as listed in regulatory documents:

Classification Examples of Documented Effects
Very Common Somnolence (daytime sleepiness), Sedation.
Common Dizziness, Ataxia (unsteadiness), Muscle Weakness, Asthenia (fatigue).
Rare Confusion, Amnesia (memory loss), Hypotension, Jaundice, Rash.
Frequency Not Known Dependence, Suicidal Ideation/Attempt, Paradoxical Reactions (e.g., agitation).

Serious Adverse Reactions and System-Organ Concerns

The official labeling highlights several serious adverse reactions, primarily related to the Central Nervous System and respiratory function. The most critical concerns documented are Respiratory Depression and the potential for developing physical and psychological dependence, particularly with higher doses or prolonged exposure. Abrupt cessation following continuous use may precipitate severe withdrawal reactions, including seizures, as noted in regulatory sources.

Concerns are formally grouped into System-Organ Classes, which include Nervous System Disorders, Psychiatric Disorders, and Respiratory, Thoracic, and Mediastinal Disorders.

Population-Specific Safety Statements

Specific safety considerations are defined for certain patient groups. Older adults are officially documented as being more susceptible to the sedative effects, dizziness, and unsteadiness, which leads to an increased risk of falls. Use is contraindicated by official labeling in individuals with severe hepatic insufficiency. Furthermore, the use of the medicine during late pregnancy or near delivery carries a documented risk of neonatal CNS depression or withdrawal symptoms in the newborn. The labeling also contains a prominent restriction regarding the use of Lorazin with opioids due to the heightened risk of profound sedation, coma, and death.

Overdose and Emergency Response

Lorazin overdose represents an exaggeration of the medicine’s core pharmacological effects as a Central Nervous System (CNS) depressant. Official regulatory documents list common manifestations such as somnolence, confusion, lethargy, slurred speech (dysarthria), and impaired coordination (ataxia). These presentations can progress to more severe, life-threatening outcomes, including profound respiratory depression, significant hypotension, and a state of deep coma.

In rare, isolated cases, and more frequently with co-ingestion of substances like alcohol or opioids, the outcome may be fatal. Regulatory warnings emphasize this combined risk factor. Elderly patients are also noted as being potentially more susceptible to profound CNS depressant effects.

Due to the potential for severe cardiorespiratory compromise, regulators mandate that a suspected overdose requires immediate medical attention. Contacting emergency services is required to ensure stabilization and close hospital monitoring of vital signs. The primary approach to management is symptomatic and supportive treatment.

While a specific antagonist, Flumazenil, is available to reverse CNS depression, its use is generally cautioned by authorities due to the documented risk of precipitating serious adverse events, such as seizures.

Therapeutic Uses of Lorazin

What Lorazin Treats: Main Uses and Benefits

Lorazin is commonly used to help manage symptoms related to heightened physiological stress and anxiety, offering supportive relief in specific, challenging situations. The primary therapeutic domains include managing anxiety disorders, providing stabilization during acute alcohol withdrawal syndrome, and offering supportive symptomatic relief for severe, continuous seizure activity known as Status Epilepticus. It is also considered relevant as a premedication before medical procedures and for short-term assistance with anxiety-related insomnia.


Short-Term Relief of Severe Anxiety and Tension

The medication is applied in contexts where symptoms like excessive worry, constant internal tension, and emotional distress create noticeable interference with daily functioning. This supportive benefit supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. “It is generally applied in settings where symptoms create noticeable functional strain and require temporary assistance in stabilization.”

Temporary Assistance in Acute Neuro-Behavioral Crises

Lorazin is relevant in clinical settings that involve acute or unstable symptom patterns, such as managing continuous, severe convulsive activity and the severe neuro-behavioral manifestations of alcohol withdrawal. It supports general well-being during symptomatic phases and is applied in addressing symptoms of increased neurological or muscular activity.

Quick Fact: Relief for Acute Symptoms
Symptom Category: Tension and Restlessness
Benefit Focus: Supportive relief
Typical Context: Acute anxiety, pre-procedure, or emergency stabilization

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Lorazin (lorazepam) is strictly defined by regulatory authorities based on contraindications, patient age, and underlying health conditions.

Populations for Whom Use is Prohibited (Contraindications)

Contraindication Authority Status
Hypersensitivity to benzodiazepines or formulation components Contraindicated
Acute Narrow-Angle Glaucoma Contraindicated
Severe Respiratory Depression or Sleep Apnoea Syndrome Contraindicated
Severe Hepatic Insufficiency Contraindicated (Risk of Encephalopathy)

Age-Related and Conditional Eligibility Rules

  • Children: Safety and effectiveness for oral use (e.g., anxiety) are generally not established in patients under 12 years of age. Use in pediatric populations is typically restricted to specific acute clinical settings.
  • Older Adults (Geriatric): Use requires caution. A lower initial dosage is officially recommended due to increased susceptibility to effects such as sedation.
  • Pregnancy and Lactation: Use is not recommended during pregnancy, particularly late in gestation due to risk to the neonate. Breastfeeding is also not recommended as the drug is excreted in breast milk.
  • Other Restrictions: Patients with compromised respiratory function (e.g., COPD), myasthenia gravis, or a history of substance abuse require caution. The medicine is not recommended as monotherapy for primary depressive disorders or psychosis.

What should I know about interactions with other medicines?

Lorazin Interactions with other medicines and products

When taking Lorazin, it is critical to be aware of the interactions with other substances, as some combinations can lead to severe health risks. This information is based strictly on authoritative regulatory documentation.

Major Interaction Categories

Interacting Product Category Official Constraint or Requirement
Opioids and CNS Depressants Use must be closely monitored and limited to the minimum necessary duration and dosage. Avoid concurrent use with alcohol, sedating antihistamines, antipsychotics, and other CNS depressants due to the risk of additive effects, including profound sedation and serious breathing difficulties.
Specific Drug Metabolism Inhibitors Co-administration with certain medicines, such as valproate and probenecid, affects how Lorazin is broken down in the body. This interaction may require a Lorazin dose reduction of approximately 50% to manage the risk of increased effects.
Food and Beverage Consumption of alcohol must be strictly avoided as it significantly increases the central nervous system depressant effects of Lorazin.
Laboratory Tests Lorazin is documented to interfere with the results of certain specific diagnostic laboratory tests.

Always ensure your healthcare provider is aware of all prescription and non-prescription medicines, vitamins, and herbal products you are taking.

Mechanism of Action

The mechanism of action for Lorazin centers on its function as an L-type calcium channel blocker, specifically targeting the voltage-dependent calcium channels ( VDCCs) predominantly located in the vascular smooth muscle of the peripheral and coronary circulations. Lorazin binds to specific subunits of these L-type VDCCs, a molecular interaction that competitively inhibits the influx of extracellular calcium ions ( Ca^2+) into the smooth muscle cell cytoplasm.

This reduction in intracellular Ca^2+ concentration limits the activation of the calcium-calmodulin-myosin light chain kinase ( MLCK) signaling cascade. Since MLCK activation is necessary for myosin phosphorylation and subsequent muscle fiber contraction, the consequence of this pathway modulation is smooth muscle relaxation, resulting in vasodilation (widening of the blood vessels).

The resulting increase in vessel diameter decreases the resistance to blood flow, leading to a reduction in systemic vascular resistance ( SVR). This system-level physiological consequence modulates the pressure gradient against which the heart pumps.

Dosage and Administration Information

Lorazin is administered via multiple official routes, reflecting its varied clinical application, including oral ingestion (tablets, solution, extended-release capsules) and parenteral delivery through intravenous (IV) or intramuscular (IM) injection. The standard oral dosage for general use typically initiates at 2 to 3 mg daily, administered in divided doses two or three times per day, but may range up to a maximum of 10 mg/day in severe contexts. Conversely, treatment for insomnia uses a single dose of 2 to 4 mg taken at bedtime.

For acute, time-critical clinical events such as Status Epilepticus, the intravenous dose is 4 mg, which may be repeated once after 10-15 minutes, up to an 8 mg maximum. Administration instructions address specific logistical needs: the oral form can be taken with or without food, but the injectable solution must be diluted 1:1 with a compatible solution before slow IV administration, and extended-release capsules must not be chewed.

A mandatory procedural rule requires that treatment be restricted to short periods, typically 2 to 4 weeks, as efficacy for long-term use is not established. Furthermore, the official protocol requires a gradual dosage-tapering schedule when discontinuing the medicine after extended therapy. Dosage must be adjusted for specific populations, notably requiring the initial dose to be reduced by approximately 50% for older or debilitated adults.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lorazin

Clinical research exploring Lorazin (lorazepam) primarily examines its use in short-term and acute care settings. Evidence comes mainly from controlled studies and systematic reviews, which describe the medicine's activity relative to an inactive substance (placebo) or other agents. Findings describe group patterns observed in the studies and provide context, but they do not determine how an individual will respond.


Evidence for Use in Short-Term Relief of Anxiety Disorders

Research for anxiety was studied using short-term Randomized Controlled Trials (RCTs). These designs compared lorazepam against a placebo or other agents evaluated for anxiety relief. The studies monitor outcomes related to physical discomfort and acute changes using standardized measures. Studies report measurements taken over observation periods, often lasting up to approximately four months, focusing on adult outpatients. Data show patterns related to short-term changes in symptom intensity.


Evidence for Use in Acute Neuro-Behavioral Stabilization

For acute, time-sensitive clinical situations, the research evidence is focused on stabilization and rapid change. Lorazepam was studied for its use in managing severe, continuous convulsive activity (Status Epilepticus) and Acute Alcohol Withdrawal Syndrome (AWS).

Research for seizures consists of RCTs that explored rapid outcomes, such as the rate at which seizure activity stopped within specific time intervals across both adult and pediatric populations. For AWS, studies examined lorazepam in hospitalized adult patients, focusing on measurements on withdrawal severity scales. Comparative evidence with certain non-benzodiazepine agents is still an an area where data are still emerging and findings were mixed in some studies.


Long-Term Evidence and Duration of Effects

Systematic clinical studies for duration of use beyond four months have not been completed. Lorazepam was observed in trials assessing short-term or episodic symptom patterns, and the vast majority of studies have follow-up durations that were limited to a few weeks or months. This means that long-term effects are not fully established.


Evidence in Specific Groups and Populations

Research examined older adults, and data show patterns that these patients may be more susceptible to certain systemic changes. Data for this group remain insufficient compared to younger adults. For children and adolescents, formal regulatory approval for oral forms for anxiety has typically been established only for those aged 12 years and older.

Key Studies & References

  1. Public Assessment Report Scientific discussion Lorazepam GenRx 1 mg and 2.5 mg tablets (lorazepam) (EMA/NL)

Frequently Asked Questions (FAQ)

Common questions about Lorazin (FAQ)

Q: What is the main reason doctors prescribe Lorazin?

A: Lorazin is officially prescribed for the management of anxiety disorders. It also holds approvals for use in acute, time-sensitive clinical events, specifically Status Epilepticus (severe seizures) and Acute Alcohol Withdrawal Syndrome.

Q: Is Lorazin an antidepressant or an anti-anxiety medicine?

A: Lorazin is officially indicated for the management of anxiety disorders and for the short-term relief of anxiety symptoms. As a benzodiazepine, its primary effects are classified as anxiolytic (anxiety-reducing). Official prescribing information states that it is not recommended for use as the only treatment for a primary depressive disorder.

Q: Can I take Lorazin every day?

A: Official guidance recommends that continuous use be restricted to the shortest duration possible. This caution is advised because the effectiveness of the medicine has not been fully established in systematic clinical studies for use longer than a few weeks.

Q: How quickly does Lorazin start working for most people?

A: Oral forms of Lorazin typically begin to provide a noticeable effect in approximately 20 to 30 minutes after use. The primary sedative effect often lasts for a duration of six to eight hours.

Q: Is Lorazin effective for managing panic attacks?

A: The official regulatory indication for Lorazin is for generalized anxiety disorders. Based on its effects, it may be used to address acute symptoms of conditions like panic disorder, though the official indication is for generalized anxiety disorders.

Q: Is it possible to develop a tolerance to the effects of Lorazin?

A: The development of tolerance is an anticipated risk associated with extended use of Lorazin. Tolerance means the body may require a higher amount over time to achieve the same effect, and this risk increases with the duration of use.

Q: Does Lorazin lose its effectiveness over time?

A: The potential for a loss of effectiveness over time, known as tolerance, is a known risk. Regulatory authorities restrict continuous use to short periods to help maintain the therapeutic benefit and mitigate the risk of this effect.

Q: What is the typical timeframe before the full benefits of Lorazin are expected?

A: Lorazin begins working quickly (within 20-30 minutes), and the beneficial effects may be noticed rapidly or over a period of days, depending on the condition being managed. The full therapeutic effect is typically observed during the limited, short course of treatment that is generally recommended.

Q: What is the purpose of the 'black box warning' often associated with medicines in this class?

A: The FDA requires a Boxed Warning—often referred to as a black box warning—to highlight the most serious risks. For Lorazin, this warning primarily informs patients about the serious dangers of abuse, misuse, addiction, dependence, and severe breathing problems that can occur when it is combined with opioids.

Q: Why do official documents refer to Lorazin as a Schedule IV controlled substance?

A: Lorazin (lorazepam) is classified as a Schedule IV controlled substance under federal law. This classification indicates that the medicine has an accepted medical use but still carries a recognized, though lower, potential for abuse and dependence relative to more restricted substances.

Q: Can Lorazin be used by people with a history of alcohol use?

A: The risk of developing physical and psychological dependence on Lorazin is known to be increased in patients with a history of alcoholism or substance abuse. Regulatory documents advise using the drug with caution in this population and emphasize limiting the overall duration of treatment.

Q: Is Lorazin suitable for people over the age of 65?

A: Use in older adults requires official caution. Official prescribing information indicates that the initial starting dose is typically lower for this population due to increased susceptibility to sedative effects. Older adults may be more susceptible to common side effects such as sedation, dizziness, and unsteadiness.

Q: Is it safe to use Lorazin if I have kidney problems?

A: The primary processing of Lorazin occurs in the liver, and its inactive form is eliminated by the kidneys. Official documents indicate that no specific dose adjustment based solely on typical kidney function changes is generally recommended, as the medicine is primarily processed in the liver.

Q: Does taking Lorazin affect my ability to drive or operate machinery?

A: The official labeling provides a clear warning regarding activities requiring full alertness. Due to the potential for the medicine to cause sleepiness, dizziness, and reduced motor skills, the official labeling advises avoiding driving or operating heavy machinery until the user is certain of how Lorazin affects their coordination and alertness.

Q: Can Lorazin affect changes in mood or personality?

A: Official safety information lists potential adverse reactions that fall under Psychiatric Disorders, including mental confusion, restlessness, and irritability. Regulatory documents note that existing depression may be revealed or worsen during benzodiazepine use.

Q: Does Lorazin affect sleep patterns or dreams?

A: Regulatory safety documents indicate the potential for general sleep disturbances and an effect known as "rebound insomnia," where sleeplessness returns or worsens after stopping use. Additionally, rare reports have noted complex sleep behaviors in patients taking medicines in this class for sleep.

Q: Can Lorazin cause stomach upset or digestive issues?

A: While stomach upset is not generally listed among the most common adverse reactions, regulatory summaries indicate that gastrointestinal effects like nausea or diarrhea may be noted as symptoms of withdrawal if the medicine is abruptly stopped.

Q: Are there any documented interactions between Lorazin and common pain relievers?

A: Regulatory drug interaction data indicates that Lorazin is not known to interact negatively with common over-the-counter pain relievers such as ibuprofen, aspirin, or acetaminophen. This information is based on checks against official drug databases.

Q: Does Lorazin interact with blood pressure medication?

A: Lorazin is documented to sometimes cause hypotension (low blood pressure) as an adverse reaction, though rarely. For patients taking blood pressure medication, caution is advised, and it is recommended that all concurrent treatments be disclosed to a healthcare provider for proper monitoring.

Q: Can Lorazin interact with supplements like melatonin or multivitamins?

A: Regulatory documents caution that using Lorazin alongside other Central Nervous System (CNS) depressants may lead to an increased risk of side effects like profound sedation. Because some supplements, such as melatonin, have sedative properties, patients are advised to inform their healthcare provider about all non-prescription products they are using.

Q: Does Lorazin interact with birth control pills?

A: Regulatory guidance indicates that Lorazin is not documented to affect the effectiveness of most hormonal birth control methods, including oral contraceptive pills. However, some types of contraceptives may potentially reduce the efficacy of the lorazepam itself.

Q: Is there a generic version of Lorazin available?

A: Yes, the active ingredient, lorazepam, is widely available as a generic drug. This is indicated by its marketing status, which permits the drug to be manufactured and sold by different companies under its chemical name.

How should Lorazin be stored and disposed of?

Storage & Disposal Map: Official Regulatory Information

Storage & Disposal Scope Official Labeled Requirement
Temperature Requirements Store the product between 20 C to 25 C (68 F to 77 F), or below 30 C.
Protection Requirements Must be kept in the original, tightly sealed container to protect from light and moisture.
Handling / Prohibitions Keep the liquid form from freezing. Avoid storing near excess heat or direct light. Orally disintegrating tablets must be used immediately upon opening the individual blister.
Child Protection The medicine must be kept out of the reach of children.
Disposal Requirements Dispose of any unused or expired product according to local regulations. Avoid allowing the product to enter wastewater or the environment.

The regulatory profile defines strict environmental controls, primarily requiring storage at controlled room temperature and protection from light and moisture to maintain product quality. The liquid formulation includes a specific prohibition against freezing. Official documents mandate that disposal must adhere to local pharmaceutical waste procedures to prevent the product's active substance from contaminating water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorazin found in:

A-Z Index: